Policy & Regulation
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
6 May 2025 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Tuesday that it has received European Commission approval for Calquence (acalabrutinib) in combi...
Bavarian Nordic secures USD143.6m US government contract for freeze-dried smallpox/mpox vaccine supply
6 May 2025 - Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Tuesday that the US Biomedical Advanced Research and Development Authority (BARDA) has exercised contract option...
Odylia Therapeutics undertakes gene replacement therapy project for NPHP1 retinal dystrophy
6 May 2025 - Odylia Therapeutics, a US-based nonprofit (501(c)3) biotechnology company focused on advancing treatments for rare diseases, announced on Monday its latest pipeline project: a co-developm...
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study
6 May 2025 - Phanes Therapeutics Inc, a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced on Monday that the first patient has been dosed in th...
Beijing Tide's AT2R antagonist TRD205 advances to Phase II trial in chronic post-surgical neuropathic pain
6 May 2025 - Beijing Tide Pharmaceutical Co Ltd, a subsidiary of China-based Sino Biopharmaceutical Limited (HK:1177), announced on Monday that it has achieved a milestone in developing its first-in-c...
FDA accepts Novo Nordisk's filing application for oral semaglutide 25 mg
5 May 2025 - Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) announced on Friday that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submi...